Neurourology/Urodynamics
10 cases on escalating oral therapy versus injection for neurogenic detrusor overactivity, onabotulinumtoxinA dosing at the labeled ceiling, isolated leak-point-pressure surveillance findings, autonomic dysreflexia prophylaxis with a PDE5-inhibitor/nitrate interaction, off-label alpha-blockade for detrusor-sphincter dyssynergia, asymptomatic bacteriuria versus true infection on intermittent catheterization, anticholinergic burden and dementia risk in a young patient, dopaminergic versus bladder-directed therapy in Parkinson disease, and desmopressin for nocturnal polyuria in multiple sclerosis — choose a case below to open its full multi-voice debate.
A spinal cord injury patient's oxybutynin is already near its practical ceiling and still failing him. The disagreement is whether the fix is a second drug, a substituted one, or leaving oral therapy behind entirely.
A woman with lifelong spina bifida is still incontinent on a maximal antimuscarinic dose. The disagreement is whether to push oral therapy further with a second agent or stop iterating on pills altogether.
A man with multiple sclerosis who has never catheterized is being offered a treatment proven to control his incontinence but shown, in the same trials, to sometimes cause the very dependency he has spent years avoiding.
A young man with spina bifida has a single elevated pressure reading on surveillance urodynamics and no symptoms at all. The disagreement is whether that number alone justifies starting a drug he doesn't otherwise need.
A pre-printed order set for autonomic dysreflexia during urodynamics calls for sublingual nitrate. The patient already takes a PDE5 inhibitor daily — and the two together are the single most dangerous combination in his chart.
A man voiding on his own but emptying poorly wants to avoid starting intermittent catheterization. The alternative on the table has almost no trial support and no label for what he actually has.
Every patient on intermittent catheterization is colonized, and the guideline is clear that colonization alone isn't treated. The disagreement is whether this particular set of symptoms is still just colonization.
The literature linking bladder anticholinergics to dementia risk was built in patients over 55. A 31-year-old on the same drug for a different reason, and for far longer, doesn't fit that literature either way.
A woman's worsening urgency could be ordinary overactive bladder or a dopaminergic problem wearing a bladder's clothing. Which one it is changes whose prescription gets adjusted first.
A drug that could finally let her sleep through the night carries a hyponatremia risk whose early symptoms — fatigue, fogginess — are indistinguishable from the disease she already has.